Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01424878 · ClinicalTrials.gov registry record
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
A clinical trial of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT01424878 is a study of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2 that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01424878, a study of Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-cells and in hereditary cases the first pathological disorder is C-cell hyperplasia (CCH) Most patients with MTC have advanced disease at the time of diagnosis. Chemotherapy and external beam radiotherapy have been minimally effective. Molecular targeted therapeutics (MTTs) and other receptor kinases in patients with advanced MTC have demonstrated activity. Despite some clinical responses, the collection of tumor tissues and autologous normal tissues has been virtually non-existent. Thus, laboratory studies defining affected molecular targets and downstream pathways, and molecular data providing direction for future clinical trials has yet to occur. Data from molecular studies of tumor tissue of hereditary or sporadic MTC patients will assist in predicting clinical behavior and the biology of MTC in predicting response to a given MTT, and in designing combination clinical trials. Objectives: Clarify how normal molecular pathways are altered by mutations in the RET protooncogene. Including additional genetic mutations and unidentified chromosomal translocations. Correlate results from molecular analyses of MTC tissue with patient s clinical course. Define how the molecular and clinical data will be useful in designing targeted therapy for patients with MTC. Eligibility: Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University. Design: Paraffin blocks of MTC tissues from archival samples at Washington University Department of Pathology will be selected. H\&E slide from selected tissue blocks will be examined for molecular study suitability. Necessary tissue
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-07-05 |
| Est. Completion | 2014-02-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01424878
The ClinicalTrials.gov registry entry for NCT01424878 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Medullary Thyroid Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT01424878 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01424878 about?
NCT01424878 is a clinical study titled "Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients". Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carcinoma (FMTC). The MTC arises from the neural crest C-...
What is the current status of trial NCT01424878?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2010-07-05. Estimated completion is 2014-02-12.
What conditions does trial NCT01424878 study?
This clinical trial studies the following conditions: Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2.
Who is sponsoring clinical trial NCT01424878?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01424878 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Medullary Thyroid Carcinoma
All registered trials for this condition
Multiple Endocrine Neoplasia Type 2
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.